ASCO Member Testifies Before Senate Committee on Current Nationwide Shortage of Certain Cancer Drugs
source: unsplash.com

ASCO Member Testifies Before Senate Committee on Current Nationwide Shortage of Certain Cancer Drugs

According to a recent American Society of Clinical Oncology (ASCO) press release, Dr. Jason Westin provided testimony regarding a nationwide shortage of cancer drugs, numbering more than 15 on the…

Continue Reading ASCO Member Testifies Before Senate Committee on Current Nationwide Shortage of Certain Cancer Drugs
ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements
PDPics / Pixabay

ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements

  Have you ever heard of Orphan Drug designation? This designation, granted by the U.S. Food and Drug Administration (FDA), is given to drugs or biologics that are designed to treat,…

Continue Reading ICYMI: LP-284 Earns Orphan Drug Designation for High-Grade B-Cell Lymphoma with MYC/BCL2 Rearrangements
Real-World Study: An Effective Combination for Young Acute Myeloid Leukemia Patients
source: shutterstock.com

Real-World Study: An Effective Combination for Young Acute Myeloid Leukemia Patients

The treatment of young patients with R/R acute myeloid leukemia (AML) poses a challenge for clinicians. Chemotherapy regimens, such as high doses of cytarabine, fludarabine, and other salvage reduction therapies,…

Continue Reading Real-World Study: An Effective Combination for Young Acute Myeloid Leukemia Patients
The Telemedicine Revolution: Reshaping Primary Healthcare for Better or Worse?
source: shutterstock.com

The Telemedicine Revolution: Reshaping Primary Healthcare for Better or Worse?

The increasing penetration of digital technologies and the ubiquity of smartphones and the internet have transformed several spheres of our lives. Healthcare is no exception. With technological advances, it has…

Continue Reading The Telemedicine Revolution: Reshaping Primary Healthcare for Better or Worse?
Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study
https://unsplash.com/photos/Y14ONzYtxb4

Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study

  Last year, the FDA placed a clinical hold on an Investigational New Drug (IND) application for deucrictibant for the on-demand and prophylactic treatment of individuals living with hereditary angioedema…

Continue Reading Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study

Takeda Announces Positive Results for TYK279 to Treat Patients with Active Psoriatic Arthritis

Takeda presented encouraging results from the Phase 2b trial (NCT05153148) at the November 2023 American College of Rheumatology (ACR) convergence in San Diego. The Phase 2b study evaluated TYK279 which…

Continue Reading Takeda Announces Positive Results for TYK279 to Treat Patients with Active Psoriatic Arthritis